A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes
Launched by NOVARTIS · Jul 11, 2006
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with type 2 diabetes at least 3 months prior to screening
- • Blood glucose criteria must be met
- • On stable dose of metformin therapy
- • BMI less than or equal to 39
- Exclusion Criteria:
- • Type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes
- • Treatment with thiazolidinediones or use of insulin within the previous 3 months
- • Significant illness within 2 weeks prior to dosing
- • High fasting triglycerides as defined by the protocol
- • Other protocol-defined inclusion/exclusion criteria may apply
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
David Kelley, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials